Analysis of IFoBM-ND episodes in comparison to diarrhoeal episodes
| Subjects, samples, episodes | 0–6 months | 6–12 months | 12–18 months | 18–24 months | Total (%) | |
|---|---|---|---|---|---|---|
| 1 | Cohort children followed (n=140) | 140 | 130 | 112 | 70 | 140 |
| 2 | Total samples | 1724 | 1603 | 1381 | 864 | 5572 |
| 3 | Total OPV-negative samples | 1078 | 1430 | 1268 | 769 | 4545 |
| 4 | Total NPEV-positive samples | 260 | 179 | 135 | 84 | 638/4545 (14.0) |
| 5 | Total NPEV-negative samples | 818 | 1251 | 1133 | 685 | 3907/4545 (86.0) |
| 6 | Total NPEV episodes | 162 | 115 | 76 | 50 | 403/4545 (8.9) |
| 7 | NPEV+ve-acute episodes (%) | 103/162 (63.6) | 83/115 (72.2) | 49/76 (64.5) | 33/50 (66.0) | 268/403 (66.5) |
| Acute diarrhoeal episodes | 19 | 13 | 10 | 6 | 48/403 (11.9) | |
| NPEV-AIFoBM-ND/total NPEV-IFoBM-ND episodes (%) | 25/61 (41.0) | 21/61 (34.4) | 9/61 (14.8) | 6/61 (9.8) | 61/115 (53.0) | |
| NPEV-AIFoBM-ND/total NPEV episodes (%) | 25/162 (15.4) | 21/115 (18.3) | 9/76 (11.8) | 6/50 (12.0) | 61/403 (15.1) | |
| NPEV-acute symptomatic (IFoBM+diarrhoea) | 44 | 34 | 19 | 12 | 109/403 (27.1) | |
| Acute asymptomatic NPEV episodes | 59 | 49 | 30 | 21 | 159/403 (39.5) | |
| 8 | NPEV-positive persistent episodes | 59 | 32 | 27 | 17 | 135 |
| NPEV-positive PD episodes (%) | 7/162 (4.3) | 7/115 (6.1) | 9/76 (11.8) | 2/50) (4.0) | 25/403 (6.2) | |
| NPEV-PIFoBM-ND/total NPEV-PIFoBM-ND (%) | 26*/54 (48.2) | 12/54 (22.2) | 9/54 (16.7) | 7/54 (13.0) | 54/115 (47.0) | |
| NPEV-PIFoBM-ND/total NPEV episodes (%) | 26/162 (16.0) | 12/115 (10.4) | 9/76 (11.8) | 7/50 (14.0) | 54/403 (13.4) | |
| NPEV-persistent symptomatic (PD+PIFoBM-ND) | 33 | 19 | 18 | 9 | 79/403 (19.6) | |
| Persistent asymptomatic NPEV episodes | 26 | 13 | 9 | 8 | 56/403 (13.9) | |
| 9 | Non-NPEV-IFoBM-ND episodes | 15 | 6 | 2 | 1 | 24/139 (17.3) |
| 10 | NPEV-IFoBM-ND/total NPEV-IFoBM-ND (%) | 51/115 (44.4) | 33/115 (28.7) | 18/115 (15.6) | 13/115 (11.3) | 115/403 (28.5) |
| NPEV-IFoBM-ND/total NPEV- +non-NPEV-IFoBM-ND (%) | 51/139 (36.7) | 33/139 (23.7) | 18/139 (12.9) | 13/139 (9.4) | 115/139 (82.7) | |
| Total NPEV-IFoBM-ND/total non-diarrhoeal episodes (%) | 51/330 (15.5) | 33/330 (10.0) | 18/330 (5.5) | 13/330 (3.9) | 115/330 (34.9) | |
| 11 | NPEV diarrhoeal episodes/NPEV infection episodes (%) | 26/162 (16.1) | 20/115 (17.4) | 19/76 (25.0) | 8/50 (16.0) | 73/403 (18.0) |
| 12 | NPEV symptomatic episodes/period (%) | 77/162 (47.5) | 53/115 (46.1) | 37/76 (48.7) | 21/50 (42.0) | 188/403 (46.7) |
| NPEV symptomatic episodes/total NPEV episodes (%) | 77/403 (17.0) | 53/403 (13.2) | 37/403 (9.2) | 21/403 (5.2) | ||
| 13 | NPEV asymptomatic episodes/period (%) | 85/162 (52.5) | 62/115 (53.9) | 39/76 (51.3) | 29/50 (58.0) | 215/403 (53.3) |
| NPEV asymptomatic episodes/total NPEV episodes (%) | 85/403 (21.1) | 62/403 (15.4) | 39/403 (9.7) | 29/40 (6.9) | ||
| NPEV asymptomatic episodes/non-diarrhoeal episodes (%) | 85/330 (25.8) | 62/330 (18.8) | 39/330 (11.8) | 29/330 (8.8) | 215/330 (65.2) | |
| 14 | RV diarrhoea/RV episodes (%) | 16/49 (32.7) | 14/23 (60.9) | 7/15 (46.7) | 5/9 (55.6) | 42/96 (43.7) |
| 15 | NPEV-RV-positive episodes | 15 | 4 | 4 | 2 | 25/4545 (0.5) |
| 16 | NPEV+RV-diarrhoeal episodes/total diarrhoeal episodes (%) | 9/193 (4.6) | 1 (0.5) | 1 (0.5) | 1 (0.5) | 12/193 (6.2) |
| 17 | Diarrhoea due to other agents/total diarrhoea (%) | 25/193 (12.9) | 20/193 (10.3) | 13/193 (6.7) | 8/193 (4.1) | 66/193 (34.2) |
*One PIFoBM-ND episode was of NPEV-RV mixed infection.
Details of diarrhoeal episodes, OPV samples, NPEV-positive and NPEV-negative samples have been described in detail previously.30
AIFoBM, acute increased frequency of bowel movements; IFoBM-ND, non-diarrhoeal IFoBM; NPEV, non-polio enterovirus; OPV, oral polio vaccine; PD, persistent diarrhoea; PIFoBM-ND, persistent IFoBM-ND; RV, rotavirus.